Logo image of CCRN

CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis

NASDAQ:CCRN - Nasdaq - US2274831047 - Common Stock - Currency: USD

13.57  -0.46 (-3.28%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CCRN. CCRN was compared to 103 industry peers in the Health Care Providers & Services industry. While CCRN has a great health rating, there are worries on its profitability. CCRN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CCRN was profitable.
In the past year CCRN had a positive cash flow from operations.
In multiple years CCRN reported negative net income over the last 5 years.
CCRN had a positive operating cash flow in 4 of the past 5 years.
CCRN Yearly Net Income VS EBIT VS OCF VS FCFCCRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

1.2 Ratios

The Return On Assets of CCRN (-3.08%) is comparable to the rest of the industry.
With a Return On Equity value of -4.24%, CCRN perfoms like the industry average, outperforming 47.57% of the companies in the same industry.
Industry RankSector Rank
ROA -3.08%
ROE -4.24%
ROIC N/A
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
CCRN Yearly ROA, ROE, ROICCCRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

In the last couple of years the Operating Margin of CCRN has declined.
CCRN's Gross Margin of 20.32% is in line compared to the rest of the industry. CCRN outperforms 40.78% of its industry peers.
CCRN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CCRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.32%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
CCRN Yearly Profit, Operating, Gross MarginsCCRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

9

2. Health

2.1 Basic Checks

CCRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CCRN has been reduced compared to 1 year ago.
The number of shares outstanding for CCRN has been reduced compared to 5 years ago.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCRN Yearly Shares OutstandingCCRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CCRN Yearly Total Debt VS Total AssetsCCRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 4.88 indicates that CCRN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.88, CCRN belongs to the top of the industry, outperforming 82.52% of the companies in the same industry.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.88
ROIC/WACCN/A
WACC9.02%
CCRN Yearly LT Debt VS Equity VS FCFCCRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.98 indicates that CCRN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.98, CCRN belongs to the best of the industry, outperforming 87.38% of the companies in the same industry.
CCRN has a Quick Ratio of 2.98. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.98, CCRN belongs to the best of the industry, outperforming 87.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.98
Quick Ratio 2.98
CCRN Yearly Current Assets VS Current LiabilitesCCRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CCRN have decreased strongly by -79.49% in the last year.
CCRN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.57% yearly.
CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.16%.
CCRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%

3.2 Future

CCRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.79% yearly.
Based on estimates for the next years, CCRN will show a decrease in Revenue. The Revenue will decrease by -0.05% on average per year.
EPS Next Y-28.98%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue Next Year-11.34%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CCRN Yearly Revenue VS EstimatesCCRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
CCRN Yearly EPS VS EstimatesCCRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 42.41, which means the current valuation is very expensive for CCRN.
Compared to the rest of the industry, the Price/Earnings ratio of CCRN is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.34, CCRN is valued quite expensively.
A Price/Forward Earnings ratio of 27.43 indicates a quite expensive valuation of CCRN.
CCRN's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.03, CCRN is valued a bit more expensive.
Industry RankSector Rank
PE 42.41
Fwd PE 27.43
CCRN Price Earnings VS Forward Price EarningsCCRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

CCRN's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, CCRN is valued cheaply inside the industry as 96.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.99
EV/EBITDA 29.56
CCRN Per share dataCCRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.73
EPS Next 2Y4.85%
EPS Next 3Y10.79%

More info and screens

0

5. Dividend

5.1 Amount

CCRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSS COUNTRY HEALTHCARE INC

NASDAQ:CCRN (6/23/2025, 12:00:46 PM)

13.57

-0.46 (-3.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners99.95%
Inst Owner Change5.81%
Ins Owners5.71%
Ins Owner Change-0.22%
Market Cap444.82M
Analysts52.31
Price Target18.44 (35.89%)
Short Float %6.52%
Short Ratio8.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.26%
Min EPS beat(2)-66.11%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-16.07%
Min EPS beat(4)-66.11%
Max EPS beat(4)22.23%
EPS beat(8)5
Avg EPS beat(8)-5.82%
EPS beat(12)9
Avg EPS beat(12)-0.39%
EPS beat(16)13
Avg EPS beat(16)7.65%
Revenue beat(2)0
Avg Revenue beat(2)-3.28%
Min Revenue beat(2)-5.84%
Max Revenue beat(2)-0.73%
Revenue beat(4)0
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-5.84%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.29%
Revenue beat(16)8
Avg Revenue beat(16)1.65%
PT rev (1m)-2.83%
PT rev (3m)3.58%
EPS NQ rev (1m)-7.66%
EPS NQ rev (3m)-41.09%
EPS NY rev (1m)-12.96%
EPS NY rev (3m)-45.17%
Revenue NQ rev (1m)-1.58%
Revenue NQ rev (3m)-4.2%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-5.16%
Valuation
Industry RankSector Rank
PE 42.41
Fwd PE 27.43
P/S 0.35
P/FCF 3.99
P/OCF 3.71
P/B 1.06
P/tB 1.83
EV/EBITDA 29.56
EPS(TTM)0.32
EY2.36%
EPS(NY)0.49
Fwd EY3.65%
FCF(TTM)3.4
FCFY25.04%
OCF(TTM)3.65
OCFY26.93%
SpS38.38
BVpS12.76
TBVpS7.42
PEG (NY)N/A
PEG (5Y)1.73
Profitability
Industry RankSector Rank
ROA -3.08%
ROE -4.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.32%
FCFM 8.85%
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score4
Asset Turnover2.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 45.77%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion 933.79%
Profit Quality N/A
Current Ratio 2.98
Quick Ratio 2.98
Altman-Z 4.88
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
EPS Next Y-28.98%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%
Revenue Next Year-11.34%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A
EBIT growth 1Y-106.89%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year706.57%
EBIT Next 3Y126.18%
EBIT Next 5YN/A
FCF growth 1Y-44.19%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-42.96%
OCF growth 3YN/A
OCF growth 5Y85.29%